Over 75 million people worldwide suffer from neurological conditions that impair walking. Traditional rehabilitation is costly and limited, patients often receive only a few hours of therapy per week, while optimal recovery requires daily intensive sessions. The lack of home-based solutions leads to slow progress, reduced mobility, and higher long-term healthcare costs.
Autonomyo enables daily rehabilitation through a wearable robotic exoskeleton and a connected digital platform. Patients can continue therapy at home with remote supervision, ensuring consistent progress and reducing dependence on in-clinic sessions. The system supports clinics and users by bridging the gap between hospital and home recovery.
- Pilots: CHUV and Lavigny (Switzerland)
- Maturity: Prototype with clinical validation
- Capital raised: 1.4 M€
- Company Valuation: 3.2 M€
- Open Round: Yes
The solution integrates AI-based therapy adaptation, motion sensors, and a mobile app. Real-time data allows clinicians to monitor patient performance and personalize exercises remotely. Autonomyo holds exclusive IP licensed from EPFL and is currently scaling toward broader commercialization.
- Sector: Health Tech
- Country: Switzerland
- Nº of workers: 8
